164 related articles for article (PubMed ID: 31692424)
21. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
22. The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
Driscoll JJ; Minter A; Driscoll DA; Burris JK
Anticancer Agents Med Chem; 2011 Feb; 11(2):242-6. PubMed ID: 21355840
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
24. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
26. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
27. Next-generation proteasome inhibitors for cancer therapy.
Park JE; Miller Z; Jun Y; Lee W; Kim KB
Transl Res; 2018 Aug; 198():1-16. PubMed ID: 29654740
[TBL] [Abstract][Full Text] [Related]
28. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib: a new pro-apoptotic agent in cancer treatment.
Russo A; Bronte G; Fulfaro F; Cicero G; Adamo V; Gebbia N; Rizzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):55-67. PubMed ID: 20088794
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Bahleda R; Le Deley MC; Bernard A; Chaturvedi S; Hanley M; Poterie A; Gazzah A; Varga A; Touat M; Deutsch E; Massard C; Van De Velde H; Hollebecque A; Sallansonnet-Froment M; Ricard D; Taillia H; Angevin E; Ribrag V; Soria JC
Invest New Drugs; 2018 Aug; 36(4):619-628. PubMed ID: 29094232
[TBL] [Abstract][Full Text] [Related]
32. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
33. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.
Zavrski I; Jakob C; Kaiser M; Fleissner C; Heider U; Sezer O
Recent Results Cancer Res; 2007; 176():165-76. PubMed ID: 17607924
[TBL] [Abstract][Full Text] [Related]
34. Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Orlowski RZ; Zeger EL
Expert Opin Investig Drugs; 2006 Feb; 15(2):117-30. PubMed ID: 16433592
[TBL] [Abstract][Full Text] [Related]
35. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
36. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
Huang Z; Wu Y; Zhou X; Xu J; Zhu W; Shu Y; Liu P
Future Oncol; 2014 Aug; 10(10):1795-807. PubMed ID: 25303058
[TBL] [Abstract][Full Text] [Related]
39. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib: proteasome inhibition as an effective anticancer therapy.
Richardson PG; Mitsiades C
Future Oncol; 2005 Apr; 1(2):161-71. PubMed ID: 16555986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
